Ursula Grohmann

List of Publications by Year
in descending order

102	11,960	50276 46	34986 98
papers	citations	h-index	g-index

106	106	106	11611
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Modulation of tryptophan catabolism by regulatory T cells. Nature Immunology, 2003, 4, 1206-1212.	14.5	1,172
2	CTLA-4â€“Ig regulates tryptophan catabolism in vivo. Nature Immunology, 2002, 3, 1097-1101.	14.5	1,077
3	The Combined Effects of Tryptophan Starvation and Tryptophan Catabolites Down-Regulate T Cell Receptor Î¶-Chain and Induce a Regulatory Phenotype in Naive T Cells. Journal of Immunology, 2006, 176, 6752-6761.	0.8	943
4	Tolerance, DCs and tryptophan: much ado about IDO. Trends in Immunology, 2003, 24, 242-248.	6.8	702
5	Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nature Immunology, 2011, 12, 870-878.	14.5	577
6	Aryl hydrocarbon receptor control of a disease tolerance defence pathway. Nature, 2014, 511, 184-190.	27.8	574
7	Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease. Nature, 2008, 451, 211-215.	27.8	492
8	IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-Î°B activation. Nature Reviews Immunology, 2007, 7, 817-823.	22.7	423
9	Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy. Nature Medicine, 2007, 13, 579-586.	30.7	298
10	Control of immune response by amino acid metabolism. Immunological Reviews, 2010, 236, 243-264.	6.0	273
11	CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86. Nature Immunology, 2004, 5, 1134-1142.	14.5	262
12	A Relay Pathway between Arginine and Tryptophan Metabolism Confers Immunosuppressive Properties on Dendritic Cells. Immunity, 2017, 46, 233-244.	14.3	241
13	IL-23 and IL-12 Have Overlapping, but Distinct, Effects on Murine Dendritic Cells. Journal of Immunology, 2002, 168, 5448-5454.	0.8	214
14	A Defect in Tryptophan Catabolism Impairs Tolerance in Nonobese Diabetic Mice. Journal of Experimental Medicine, 2003, 198, 153-160.	8.5	193
15	SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 20828-20833.	7.1	187
16	Toward the identification of a tolerogenic signature in IDO-competent dendritic cells. Blood, 2006, 107, 2846-2854.	1.4	183
17	IL-6 Inhibits the Tolerogenic Function of CD8Î±+ Dendritic Cells Expressing Indoleamine 2,3-Dioxygenase. Journal of Immunology, 2001, 167, 708-714.	0.8	168
18	Kynurenine Pathway Enzymes in Dendritic Cells Initiate Tolerogenesis in the Absence of Functional IDO. Journal of Immunology, 2006, 177, 130-137.	0.8	164

#	Article	IF	Citations
19	Indoleamine 2,3â€dioxygenase: From catalyst to signaling function. European Journal of Immunology, 2012, 42, 1932-1937.	2.9	160
20	Cutting Edge: Autocrine TGF-Î² Sustains Default Tolerogenesis by IDO-Competent Dendritic Cells. Journal of Immunology, 2008, 181, 5194-5198.	0.8	154
21	Metabotropic glutamate receptor-4 modulates adaptive immunity and restrains neuroinflammation. Nature Medicine, 2010, 16, 897-902.	30.7	138
22	CTLA-4â€"Ig Activates Forkhead Transcription Factors and Protects Dendritic Cells from Oxidative Stress in Nonobese Diabetic Mice. Journal of Experimental Medicine, 2004, 200, 1051-1062.	8.5	125
23	TGF-Î² and kynurenines as the key to infectious tolerance. Trends in Molecular Medicine, 2009, 15, 41-49.	6.7	121
24	The immune regulation in cancer by the amino acid metabolizing enzymes ARG and IDO. Current Opinion in Pharmacology, 2017, 35, 30-39.	3.5	114
25	CTLA-4 Blockade Confers Lymphocyte Resistance to Regulatory T-Cells in Advanced Melanoma: Surrogate Marker of Efficacy of Tremelimumab?. Clinical Cancer Research, 2008, 14, 5242-5249.	7.0	104
26	High doses of CpG oligodeoxynucleotides stimulate a tolerogenic TLR9â€"TRIF pathway. Nature Communications, 2013, 4, 1852.	12.8	102
27	IDO Mediates TLR9-Driven Protection from Experimental Autoimmune Diabetes. Journal of Immunology, 2009, 183, 6303-6312.	0.8	101
28	Functional Plasticity of Dendritic Cell Subsets as Mediated by CD40 Versus B7 Activation. Journal of Immunology, 2003, 171, 2581-2587.	0.8	100
29	IFN-Î³ Inhibits Presentation of a Tumor/Self Peptide by CD8Î±â^' Dendritic Cells Via Potentiation of the CD8Î±+ Subset. Journal of Immunology, 2000, 165, 1357-1363.	0.8	97
30	Tryptophan catabolism generates autoimmune-preventive regulatory T cells. Transplant Immunology, 2006, 17, 58-60.	1.2	97
31	Cutting Edge: Silencing Suppressor of Cytokine Signaling 3 Expression in Dendritic Cells Turns CD28-Ig from Immune Adjuvant to Suppressant. Journal of Immunology, 2005, 174, 6582-6586.	0.8	88
32	Therapy of experimental type 1 diabetes by isolated Sertoli cell xenografts alone. Journal of Experimental Medicine, 2009, 206, 2511-2526.	8.5	84
33	Immunosuppression Via Tryptophan Catabolism: The Role of Kynurenine Pathway Enzymes. Transplantation, 2007, 84, S17-S20.	1.0	82
34	Wolfram syndrome, a rare neurodegenerative disease: from pathogenesis to future treatment perspectives. Journal of Translational Medicine, 2019, 17, 238.	4.4	81
35	Eating Disorders and Disordered Eating Symptoms in Adolescents with Type 1 Diabetes. Nutrients, 2017, 9, 906.	4.1	80
36	Amino-acid sensing and degrading pathways in immune regulation. Cytokine and Growth Factor Reviews, 2017, 35, 37-45.	7.2	79

#	Article	IF	Citations
37	Ligand and cytokine dependence of the immunosuppressive pathway of tryptophan catabolism in plasmacytoid dendritic cells. International Immunology, 2005, 17, 1429-1438.	4.0	74
38	Different Partners, Opposite Outcomes: A New Perspective of the Immunobiology of Indoleamine 2,3-Dioxygenase. Molecular Medicine, 2012, 18, 834-842.	4.4	74
39	Is It Time to Use Probiotics to Prevent or Treat Obesity?. Nutrients, 2018, 10, 1613.	4.1	72
40	Polyamines and Kynurenines at the Intersection of Immune Modulation. Trends in Immunology, 2020, 41, 1037-1050.	6.8	67
41	Topical Application of Soluble CD83 Induces IDO-Mediated Immune Modulation, Increases Foxp3+ T Cells, and Prolongs Allogeneic Corneal Graft Survival. Journal of Immunology, 2013, 191, 1965-1975.	0.8	60
42	Positive allosteric modulation of indoleamine 2,3-dioxygenase 1 restrains neuroinflammation. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 3848-3857.	7.1	58
43	Indoleamine 2,3â€dioxygenase 1 (IDO1): an upâ€toâ€date overview of an eclectic immunoregulatory enzyme. FEBS Journal, 2022, 289, 6099-6118.	4.7	56
44	Immunoregulatory Interplay Between Arginine and Tryptophan Metabolism in Health and Disease. Frontiers in Immunology, 2019, 10, 1565.	4.8	55
45	Course of Primary Candidiasis in T Cell-Depleted Mice Infected with Attenuated Variant Cells. Journal of Infectious Diseases, 1992, 166, 1384-1392.	4.0	54
46	The Coevolution of IDO1 and AhR in the Emergence of Regulatory T-Cells in Mammals. Frontiers in Immunology, 2015, 6, 58.	4.8	53
47	Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma. Clinical Cancer Research, 2020, 26, 5232-5245.	7.0	52
48	Distinct roles of immunoreceptor tyrosineâ€based motifs in immunosuppressive indoleamine 2,3â€dioxygenase 1. Journal of Cellular and Molecular Medicine, 2017, 21, 165-176.	3.6	51
49	Deficiency of immunoregulatory indoleamine 2,3-dioxygenase 1in juvenile diabetes. JCI Insight, 2018, 3, .	5.0	51
50	Amino acid metabolism as drug target in autoimmune diseases. Autoimmunity Reviews, 2019, 18, 334-348.	5.8	48
51	Forced IDO 1 expression in dendritic cells restores immunoregulatory signalling in autoimmune diabetes. Journal of Cellular and Molecular Medicine, 2014, 18, 2082-2091.	3.6	47
52	Engagement of Nuclear Coactivator 7 by 3-Hydroxyanthranilic Acid Enhances Activation of Aryl Hydrocarbon Receptor in Immunoregulatory Dendritic Cells. Frontiers in Immunology, 2019, 10, 1973.	4.8	47
53	Stem cells from human amniotic fluid exert immunoregulatory function via secreted indoleamine 2,3â€dioxygenase1. Journal of Cellular and Molecular Medicine, 2015, 19, 1593-1605.	3.6	45
54	Induction of immunosuppressive functions and NF-ÎºB by FLIP in monocytes. Nature Communications, 2018, 9, 5193.	12.8	45

#	Article	IF	Citations
55	Indoleamine 2,3-Dioxygenase and Regulatory Function: Tryptophan Starvation and Beyond. Methods in Molecular Biology, 2010, 677, 269-280.	0.9	44
56	Ligand Binding and Functional Selectivity of <scp>l</scp>-Tryptophan Metabolites at the Mouse Aryl Hydrocarbon Receptor (mAhR). Journal of Chemical Information and Modeling, 2014, 54, 3373-3383.	5.4	42
57	Loss of IDO1 Expression From Human Pancreatic Î²-Cells Precedes Their Destruction During the Development of Type 1 Diabetes. Diabetes, 2018, 67, 1858-1866.	0.6	42
58	IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII. Journal of Clinical Investigation, 2015, 125, 3766-3781.	8.2	39
59	Enhanced tryptophan catabolism in the absence of the molecular adapter DAP12. European Journal of Immunology, 2005, 35, 3111-3118.	2.9	38
60	Use of a skin test assay to determine tumor-specific CD8+ T cell reactivity. European Journal of Immunology, 1994, 24, 1446-1452.	2.9	34
61	Immune Checkpoint Molecules, Personalized Immunotherapy, and Autoimmune Diabetes. Trends in Molecular Medicine, 2018, 24, 931-941.	6.7	34
62	Advances in indoleamine 2,3-dioxygenase 1 medicinal chemistry. MedChemComm, 2017, 8, 1378-1392.	3.4	33
63	CD8+ cell activation to a major mastocytoma rejection antigen, P815AB: requirement for tumâˆ’ or helper peptides in priming for skin test reactivity to a P815AB-related peptide. European Journal of Immunology, 1995, 25, 2797-2802.	2.9	30
64	LPS-conditioned dendritic cells confer endotoxin tolerance contingent on tryptophan catabolism. Immunobiology, 2015, 220, 315-321.	1.9	30
65	3-hydroxy-L-kynurenamine is an immunomodulatory biogenic amine. Nature Communications, 2021, 12, 4447.	12.8	30
66	Allosteric modulation of metabotropic glutamate receptor 4 activates IDO1-dependent, immunoregulatory signaling in dendritic cells. Neuropharmacology, 2016, 102, 59-71.	4.1	29
67	The Landscape of AhR Regulators and Coregulators to Fine-Tune AhR Functions. International Journal of Molecular Sciences, 2021, 22, 757.	4.1	29
68	The Proteasome Inhibitor Bortezomib Controls Indoleamine 2,3-Dioxygenase 1 Breakdown and Restores Immune Regulation in Autoimmune Diabetes. Frontiers in Immunology, 2017, 8, 428.	4.8	28
69	Amino Acid Metabolism in Rheumatoid Arthritis: Friend or Foe?. Biomolecules, 2020, 10, 1280.	4.0	26
70	Preclinical discovery and development of fingolimod for the treatment of multiple sclerosis. Expert Opinion on Drug Discovery, 2019, 14, 1199-1212.	5.0	25
71	Current Challenges for IDO2 as Target in Cancer Immunotherapy. Frontiers in Immunology, 2021, 12, 679953.	4.8	24
72	Class IA PI3Ks regulate subcellular and functional dynamics of IDO1. EMBO Reports, 2020, 21, e49756.	4.5	24

#	Article	IF	Citations
73	Proteasomal Degradation of Indoleamine 2,3-Dioxygenase in CD8⁺ Dendritic Cells is Mediated by Suppressor of Cytokine Signaling 3 (SOCS3). International Journal of Tryptophan Research, 2010, 3, IJTR.S3971.	2.3	23
74	Effects of probiotic administration on immune responses of children and adolescents with type 1 diabetes to a quadrivalent inactivated influenza vaccine. Human Vaccines and Immunotherapeutics, 2020, 16, 86-94.	3.3	23
75	IL-23 neutralization protects mice from Gram-negative endotoxic shock. Cytokine, 2006, 34, 161-169.	3.2	22
76	A GpC-Rich Oligonucleotide Acts on Plasmacytoid Dendritic Cells To Promote Immune Suppression. Journal of Immunology, 2012, 189, 2283-2289.	0.8	22
77	IDO1 and TGF-Î² Mediate Protective Effects of IFN-Î± in Antigen-Induced Arthritis. Journal of Immunology, 2016, 197, 3142-3151.	0.8	21
78	Tryptophan Catabolism in Nonobese Diabetic Mice. Advances in Experimental Medicine and Biology, 2003, 527, 47-54.	1.6	20
79	Bioengineering heterodimeric cytokines: turning promiscuous proteins into therapeutic agents. Biotechnology and Genetic Engineering Reviews, 2013, 29, 149-174.	6.2	19
80	Novel mutations in the WFS1 gene are associated with Wolfram syndrome and systemic inflammation. Human Molecular Genetics, 2021, 30, 265-276.	2.9	18
81	CTLA-4, T helper lymphocytes and dendritic cells: an internal perspective of T-cell homeostasis. Trends in Molecular Medicine, 2003, 9, 133-135.	6.7	17
82	Fragment-based approach to identify IDO1 inhibitor building blocks. European Journal of Medicinal Chemistry, 2017, 141, 169-177.	5.5	17
83	Immunogenicity of tumor peptides: importance of peptide length and stability of peptide/MHC class II complex. Cancer Immunology, Immunotherapy, 1999, 48, 195-203.	4.2	16
84	Xenograft of Microencapsulated Sertoli Cells Reverses T1DM in NOD Mice by Inducing Neogenesis of Beta-Cells. Transplantation, 2010, 90, 1352-1357.	1.0	16
85	A novel mutation of indoleamine 2,3-dioxygenase 1 causes a rapid proteasomal degradation and compromises protein function. Journal of Autoimmunity, 2020, 115, 102509.	6.5	14
86	New Insights from Crystallographic Data: Diversity of Structural Motifs and Molecular Recognition Properties between Groups of IDO1 Structures. ChemMedChem, 2020, 15, 891-899.	3.2	11
87	<scp>IL</scp>â€35Igâ€“expressing dendritic cells induce tolerance via Arginase 1. Journal of Cellular and Molecular Medicine, 2019, 23, 3757-3761.	3.6	9
88	Islet antigen-pulsed dendritic cells expressing ectopic IL-35Ig protect nonobese diabetic mice from autoimmune diabetes. Cytokine, 2015, 75, 380-388.	3.2	8
89	Pathogenetic Interplay Between IL-6 and Tryptophan Metabolism in an Experimental Model of Obesity. Frontiers in Immunology, 2021, 12, 713989.	4.8	8
90	Opportunities and challenges in drug discovery targeting metabotropic glutamate receptor 4. Expert Opinion on Drug Discovery, 2018, 13, 411-423.	5.0	6

#	Article	IF	Citations
91	Tracking Hidden Binding Pockets Along the Molecular Recognition Path of <scp>l</scp>â€Trp to Indoleamine 2,3â€Dioxygenase 1. ChemMedChem, 2019, 14, 2084-2092.	3.2	6
92	Critical Assessment of a Structure-Based Screening Campaign for IDO1 Inhibitors: Tips and Pitfalls. International Journal of Molecular Sciences, 2022, 23, 3981.	4.1	6
93	Challenges in the design of reliable immuno-oncology mouse models to inform drug development. Future Medicinal Chemistry, 2017, 9, 1313-1317.	2.3	4
94	Vedolizumab Tissue Concentration Correlates to Mucosal Inflammation and Objective Treatment Response in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2021, 27, 1813-1820.	1.9	4
95	TLRs and tryptophan metabolism at the crossroad of immunoregulatory pathways. Immunometabolism, 2014, 1, .	6.0	3
96	Growth and glycemic control in children with type 1 diabetes and asymptomatic celiac disease treated with a gluten -free diet for 1â€‰year. European Journal of Inflammation, 2019, 17, 205873921985557.	0.5	2
97	Reply to Han et al.: On track for an IDO1-based personalized therapy in autoimmunity. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 24037-24038.	7.1	2
98	Exemplifying complexity of immune suppression by a â€œcanonicalâ€•speech: A glimpse into TNFRSFâ€activated signaling pathways in Treg cells. European Journal of Immunology, 2020, 50, 944-948.	2.9	2
99	CTLA-4-immunoglobulin and indoleamine 2,3-dioxygenase in dominant tolerance. , 2008, , 87-106.		1
100	Correction: IDO Mediates Tlr9-Driven Protection From Experimental Autoimmune Diabetes. Journal of Immunology, 2010, 184, 7316-7316.	0.8	0
101	Microscale Thermophoresis and Docking Studies Suggest Lapachol and Auraptene are Ligands of IDO1. Natural Product Communications, 2018, 13, 1934578X1801300.	0.5	0
102	Editorial overview: Indoles: very busy (and not indolent) molecules at work in immune regulation. Current Opinion in Immunology, 2021, 70, v-vii.	5.5	0